<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Health Forum</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Health Forum</journal-id><journal-title-group><journal-title>JAMA Health Forum</journal-title></journal-title-group><issn pub-type="epub">2689-0186</issn><publisher><publisher-name>American Medical Association</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39729303</article-id><article-id pub-id-type="pmc">PMC11681369</article-id>
<article-id pub-id-type="doi">10.1001/jamahealthforum.2024.4601</article-id><article-id pub-id-type="publisher-id">ald240035</article-id><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="domain" specific-use="print"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Research Letter</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="allowCommenting"><subject>Comments</subject></subj-group></article-categories><title-group><article-title>Confirmatory Trials for Drugs Granted Conditional Approval by the Chinese National Medical Products Administration</article-title><alt-title alt-title-type="headline">Confirmatory Trials for Drugs Granted Conditional Approval in China</alt-title><alt-title alt-title-type="running-head">Confirmatory Trials for Drugs Granted Conditional Approval in China</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Tian</surname><given-names>Yun</given-names></name><degrees>PhD</degrees><xref rid="ald240035aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ald240035aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="ald240035aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiaoyong</given-names></name><degrees>MD</degrees><xref rid="ald240035aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ald240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xingyu</given-names></name><degrees>MD</degrees><xref rid="ald240035aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ald240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Jinwei</given-names></name><degrees>MD</degrees><xref rid="ald240035aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ald240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hu</surname><given-names>Shuchen</given-names></name><degrees>PhD</degrees><xref rid="ald240035aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ald240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Caijun</given-names></name><degrees>PhD</degrees><xref rid="ald240035aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ald240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Fang</surname><given-names>Yu</given-names></name><degrees>PhD</degrees><xref rid="ald240035aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="ald240035aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="ald240035aff1"><label>1</label>Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi&#x02019;an Jiaotong University, Xi&#x02019;an, China</aff><aff id="ald240035aff2"><label>2</label>Center for Drug Safety and Policy Research, Xi&#x02019;an Jiaotong University, Xi&#x02019;an, China</aff><aff id="ald240035aff3"><label>3</label>Department of Pharmacy, Shaanxi Provincial Cancer Hospital, Xi&#x02019;an, China</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> October 24, 2024.</p><p content-type="published-online"><bold>Published:</bold> December 27, 2024. doi:<uri content-type="doi">10.1001/jamahealthforum.2024.4601</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#x000a9; 2024 Tian Y et al. <italic>JAMA Health Forum</italic>.</p><corresp id="ald240035cor1"><bold>Corresponding Authors:</bold> Caijun Yang, PhD (<email xlink:href="yangcj@xjtu.edu.cn">yangcj@xjtu.edu.cn</email>), and Yu Fang, PhD (<email xlink:href="yufang@mail.xjtu.edu.cn">yufang@mail.xjtu.edu.cn</email>), School of Pharmacy, Xi&#x02019;an Jiaotong University Health Science Center, 28 Yanta West Rd, Xi&#x02019;an 710061, China.</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Profs Yang and Fang had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Tian and Xiaoyong Liu contributed equally as co&#x02013;first authors.</p><p><italic>Concept and design:</italic> Tian, Xiaoyong Liu, Xingyu Liu, Yang, Fang.</p><p><italic>Acquisition, analysis, or interpretation of data:</italic> Xiaoyong Liu, Zhang, Hu, Yang.</p><p><italic>Drafting of the manuscript:</italic> Tian, Xiaoyong Liu, Yang.</p><p><italic>Critical review of the manuscript for important intellectual content:</italic> Xiaoyong Liu, Xingyu Liu, Zhang, Hu, Yang, Fang.</p><p><italic>Statistical analysis:</italic> Tian, Xiaoyong Liu, Xingyu Liu, Zhang, Hu.</p><p><italic>Obtained funding:</italic> Yang.</p><p><italic>Administrative, technical, or material support:</italic> Zhang, Yang, Fang.</p><p><italic>Supervision:</italic> Zhang, Yang.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> None reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This work was funded by grant 72174166 from the National Natural Science Foundation of China.</p><p content-type="funding-statement"><bold>Role of Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; and the preparation, review, approval, or decision to submit the manuscript.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See the <xref rid="note-ALD240035-1-s" ref-type="supplementary-material">Supplement</xref>.</p><p><bold>Additional Contributions:</bold> The authors are grateful to the members of Center for Drug Safety and Policy Research of Xi&#x02019;an Jiaotong University for preliminary discussions.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2024-12-27T10:00"><day>27</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>12</month><year>2024</year></pub-date><!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.--><volume>5</volume><issue>12</issue><elocation-id>e244601</elocation-id><history><date date-type="received"><day>27</day><month>5</month><year>2024</year></date><date date-type="accepted"><day>24</day><month>10</month><year>2024</year></date></history><permissions><copyright-statement>Copyright 2024 Tian Y et al. <italic>JAMA Health Forum</italic>.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri content-type="pdf-version" xlink:href="jamahealthforum-e244601.pdf">jamahealthforum-e244601.pdf</self-uri><self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/channels/health-forum/fullarticle/10.1001/jamahealthforum.2024.4601"/><abstract abstract-type="teaser" specific-use="electronic"><p>This cross-sectional study analyzes differences in pivotal and confirmatory trial characteristics for drugs granted conditional approval in China.</p></abstract></article-meta></front><body><sec id="H1-1-ALD240035"><title>Introduction</title><p>In 2018, the Chinese National Medical Products Administration (NMPA) established a conditional approval (CA) program, similar to the US accelerated approval program, which uses surrogate end points for drug indications in serious or life-threatening conditions. Numerous drugs have been approved under the CA program, mainly supported by pivotal trials.<sup><xref rid="ald240035r1" ref-type="bibr">1</xref></sup> Limited evidence exists on the characteristics of confirmatory trials conducted after approval. Thus, we reviewed the confirmatory trials of all drugs receiving CA in China from January 1, 2018, to December 31, 2022, and compared their characteristics, including differences in design, with those of pivotal trials.</p></sec><sec id="H1-2-ALD240035"><title>Methods</title><p>In this cross-sectional study, we used publicly available NMPA data from ChinaDrugTrials.org and ClinicalTrials.gov to identify drug indications receiving CA. As the study did not constitute human participant research, local ethics review and informed consent were not required in accordance with the Common Rule. The study followed the <ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/strobe/" ext-link-type="uri">STROBE</ext-link> reporting guideline.</p><p>We extracted all characteristics of the 2 trial types. Descriptive statistics were collected to characterize the indications and clinical trial features, with differences analyzed using &#x003c7;<sup>2</sup> tests for categorical variables and Wilcoxon rank sum tests for continuous variables. A 2-tailed <italic>P</italic>&#x02009;&#x0003c;&#x02009;.05 was considered significant. All analyses were performed using SPSS, version 26 (IBM Corporation).</p></sec><sec id="H1-3-ALD240035"><title>Results</title><p>The NMPA granted CA to 64 drugs for 85 indications. Due to nondisclosure of several confirmatory trials by the NMPA, 53 drugs with 67 indications were included in the final analysis (<xref rid="ald240035t1" ref-type="table">Table 1</xref>). Of these 67 indications, 38 (57%) were chemical and 40 (60%) novel or primary, and 36 drugs (54%) were domestically manufactured. Conditional approval was granted primarily for oncology indications (59 [88%]), and 39 indications (58%) were included in the medical insurance catalogs.</p><table-wrap position="float" id="ald240035t1"><label>Table 1. </label><caption><title>Characteristics of 67 Indications Receiving National Medical Products Administration Conditional Approval, 2018-2022<xref rid="ald240035t1n1" ref-type="table-fn"><sup>a</sup></xref></title></caption><table frame="hsides" rules="groups"><col width="33.25%" span="1"/><col width="66.75%" span="1"/><thead><tr><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Characteristic</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">No. (%) of indications receiving conditional approval</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Fast track</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Priority review</td><td valign="top" align="left" rowspan="1" colspan="1">59 (88)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Breakthrough therapy</td><td valign="top" align="left" rowspan="1" colspan="1">3 (4)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Drug class</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chemical</td><td valign="top" align="left" rowspan="1" colspan="1">38 (57)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Biologic</td><td valign="top" align="left" rowspan="1" colspan="1">28 (42)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Chinese medicine</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Approval type</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Novel</td><td valign="top" align="left" rowspan="1" colspan="1">40 (60)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Supplemental</td><td valign="top" align="left" rowspan="1" colspan="1">18 (27)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unclear</td><td valign="top" align="left" rowspan="1" colspan="1">9 (13)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Therapeutic area</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Solid tumor</td><td valign="top" align="left" rowspan="1" colspan="1">42 (63)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hemangioma</td><td valign="top" align="left" rowspan="1" colspan="1">17 (25)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nononcology</td><td valign="top" align="left" rowspan="1" colspan="1">8 (12)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Manufacturing location</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Imported</td><td valign="top" align="left" rowspan="1" colspan="1">31 (46)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Domestic</td><td valign="top" align="left" rowspan="1" colspan="1">36 (54)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Medical insurance catalog<xref rid="ald240035t1n1" ref-type="table-fn"><sup>a</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Yes</td><td valign="top" align="left" rowspan="1" colspan="1">39 (58)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No</td><td valign="top" align="left" rowspan="1" colspan="1">28 (42)</td></tr></tbody></table><table-wrap-foot><fn id="ald240035t1n1"><label>
<sup>a</sup>
</label><p>In China, drugs covered by medical insurance are categorized into class A and class B, which have different reimbursement rates. Class A drugs are reimbursed in full according to the regulations, while for class B drugs, individuals bear a certain percentage of the cost. All indications in the table that are included in the medical insurance catalog are class B medical insurance.</p></fn></table-wrap-foot></table-wrap><p>A total of 79 pivotal and 72 confirmatory trials supported the CA of the 67 indications. Confirmatory trials were mostly randomized (48 [67%] vs 29 pivotal trials [37%]; <italic>P</italic>&#x02009;&#x0003c;&#x02009;.001) and more likely to be double masked (23 [32%] vs 11 [14%]; <italic>P</italic>&#x02009;=&#x02009;.008) (<xref rid="ald240035t2" ref-type="table">Table 2</xref>). Progression-free survival as a primary end point was more common for confirmatory (31 [43%]) vs pivotal (13 [16%]) trials (<italic>P</italic>&#x02009;&#x0003c;&#x02009;.001). Overall survival (OS) was the least used end point in both trial types (8 [10%] vs 12 [17%]). Phase 3 was most common among confirmatory trials (47 [65%]) and phase 2 among pivotal trials (46 [58%]; <italic>P</italic>&#x02009;&#x0003c;&#x02009;.001). The median (IQR) time to completion of 66 confirmatory trials (excluding 6 with none reported) was 56 (40-73) months. By December 31, 2023, 12 of 21 (57%) trials did not meet the required completion time, including 2 completed after the deadline.</p><table-wrap position="float" id="ald240035t2"><label>Table 2. </label><caption><title>Comparison of Pivotal and Confirmatory Trial Characteristics for Drugs Receiving Conditional Approval</title></caption><table frame="hsides" rules="groups"><col width="30.25%" span="1"/><col width="25.48%" span="1"/><col width="33%" span="1"/><col width="11.27%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Study characteristic</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">No. (%) of trials</th><th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Pivotal (n&#x02009;=&#x02009;79)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Confirmatory (n&#x02009;=&#x02009;72)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">No. enrolled,<xref rid="ald240035t2n1" ref-type="table-fn"><sup>a</sup></xref> median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">130 (84-334)</td><td valign="top" align="left" rowspan="1" colspan="1">202 (80-430)</td><td valign="top" align="left" rowspan="1" colspan="1">.26</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Randomized</td><td valign="top" align="left" rowspan="1" colspan="1">29 (37)</td><td valign="top" align="left" rowspan="1" colspan="1">48 (67)</td><td valign="top" align="left" rowspan="1" colspan="1">&#x0003c;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Double masked</td><td valign="top" align="left" rowspan="1" colspan="1">11 (14)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">.008</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Comparator</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Placebo</td><td valign="top" align="left" rowspan="1" colspan="1">9 (11)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (19)</td><td rowspan="5" valign="middle" align="left" colspan="1">&#x0003c;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Active</td><td valign="top" align="left" rowspan="1" colspan="1">14 (18)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (35)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Placebo and active</td><td valign="top" align="left" rowspan="1" colspan="1">2 (2)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> None</td><td valign="top" align="left" rowspan="1" colspan="1">54 (68)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (32)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unclear<xref rid="ald240035t2n2" ref-type="table-fn"><sup>b</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">5 (7)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Trial phase<xref rid="ald240035t2n3" ref-type="table-fn"><sup>c</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1</td><td valign="top" align="left" rowspan="1" colspan="1">16 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (8)</td><td rowspan="4" valign="middle" align="left" colspan="1">&#x0003c;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2</td><td valign="top" align="left" rowspan="1" colspan="1">46 (58)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (24)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3</td><td valign="top" align="left" rowspan="1" colspan="1">25 (32)</td><td valign="top" align="left" rowspan="1" colspan="1">47 (65)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 4</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">8 (11)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Primary end point<xref rid="ald240035t2n4" ref-type="table-fn"><sup>d</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ORR<xref rid="ald240035t2n5" ref-type="table-fn"><sup>e</sup></xref></td><td valign="top" align="left" rowspan="1" colspan="1">47 (59)</td><td valign="top" align="left" rowspan="1" colspan="1">20 (28)</td><td rowspan="4" valign="middle" align="left" colspan="1">&#x0003c;.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> PFS</td><td valign="top" align="left" rowspan="1" colspan="1">13 (16)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (43)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> OS</td><td valign="top" align="left" rowspan="1" colspan="1">8 (10)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (17)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other</td><td valign="top" align="left" rowspan="1" colspan="1">16 (20)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (21)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: ORR, objective response rate; OS, overall survival; PFS, progression-free survival.</p><fn id="ald240035t2n1"><label>
<sup>a</sup>
</label><p>The number of people is based on the actual enrollment. For trial status currently recruiting or before recruiting, we used the trial number of expected enrollment as a reference.</p></fn><fn id="ald240035t2n2"><label>
<sup>b</sup>
</label><p>These trials were set up with parallel control groups, but comparator information was unavailable in ClinicalTrials.gov or ChinaDrugTrials.org.</p></fn><fn id="ald240035t2n3"><label>
<sup>c</sup>
</label><p>The trial phase may be 1 or 2I, or it may be 2 or 3, so the total percentage is more than 100.</p></fn><fn id="ald240035t2n4"><label>
<sup>d</sup>
</label><p>Some primary end points were ORR and PFS or other (eg, event-free survival, time to progression), so the total percentage was more than 100.</p></fn><fn id="ald240035t2n5"><label>
<sup>e</sup>
</label><p>Complete response and partial response for hematologic indications are also classified as ORR.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H1-4-ALD240035"><title>Discussion</title><p>We found significant differences in the design and characteristics of pivotal and confirmatory trials for CA drugs in China, including randomization, masking, use of comparators, trial phase, and primary end points. These results differ from those observed in US studies, which found pivotal and confirmatory trials to have similar design characteristics.<sup><xref rid="ald240035r2" ref-type="bibr">2</xref></sup></p><p>The primary end point is crucial for determining clinical benefit.<sup><xref rid="ald240035r3" ref-type="bibr">3</xref></sup> In China, pivotal trials were more likely to use objective response rate while confirmatory trials favored progression-free survival as the primary end point, similarly to the US.<sup><xref rid="ald240035r2" ref-type="bibr">2</xref></sup> The criterion standard of OS<sup><xref rid="ald240035r4" ref-type="bibr">4</xref></sup> was underused in both pivotal and confirmatory trials. Due to poor correlation with OS,<sup><xref rid="ald240035r5" ref-type="bibr">5</xref></sup> surrogate end points may not indicate a clinical benefit. Some studies<sup><xref rid="ald240035r4" ref-type="bibr">4</xref>,<xref rid="ald240035r6" ref-type="bibr">6</xref></sup> found that nearly all accelerated approval withdrawals occurred for drugs whose confirmatory trials did not use OS as the primary end point. The NMPA should encourage companies to use OS as a primary end point in confirmatory trials, and physicians and patients should be aware of limited evidence of clinical benefits for CA drugs in China. This study used publicly available data spanning just 4 years, which limited the sample size and may have limited our ability to capture all pivotal and confirmatory trials.</p></sec></body><back><ref-list id="REF-ALD240035"><title>References</title><ref id="ald240035r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Luo</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Huang</surname>
<given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022</article-title>. <source>EClinicalMedicine</source>. <year>2023</year>;<volume>63</volume>:<elocation-id>102177</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.eclinm.2023.102177</pub-id>
<pub-id pub-id-type="pmid">37662522</pub-id>
</mixed-citation></ref><ref id="ald240035r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Naci</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Smalley</surname>
<given-names>KR</given-names></string-name>, <string-name><surname>Kesselheim</surname>
<given-names>AS</given-names></string-name></person-group>. <article-title>Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US Food and Drug Administration</article-title>. <source>JAMA</source>. <year>2017</year>;<volume>318</volume>(<issue>7</issue>):<fpage>626</fpage>-<lpage>636</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2017.9415</pub-id>
<pub-id pub-id-type="pmid">28810023</pub-id>
</mixed-citation></ref><ref id="ald240035r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Ciani</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Manyara</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Davies</surname>
<given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials</article-title>. <source>EClinicalMedicine</source>. <year>2023</year>;<volume>65</volume>:<elocation-id>102283</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.eclinm.2023.102283</pub-id>
<pub-id pub-id-type="pmid">37877001</pub-id>
</mixed-citation></ref><ref id="ald240035r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Gyawali</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Rome</surname>
<given-names>BN</given-names></string-name>, <string-name><surname>Kesselheim</surname>
<given-names>AS</given-names></string-name></person-group>. <article-title>Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study</article-title>. <source>BMJ</source>. <year>2021</year>;<volume>374</volume>:<fpage>n1959</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.n1959</pub-id>
<pub-id pub-id-type="pmid">34497044</pub-id>
</mixed-citation></ref><ref id="ald240035r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Chen</surname>
<given-names>EY</given-names></string-name>, <string-name><surname>Haslam</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Prasad</surname>
<given-names>V</given-names></string-name></person-group>. <article-title>FDA acceptance of surrogate end points for cancer drug approval: 1992-2019</article-title>. <source>JAMA Intern Med</source>. <year>2020</year>;<volume>180</volume>(<issue>6</issue>):<fpage>912</fpage>-<lpage>914</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamainternmed.2020.1097</pub-id>
<pub-id pub-id-type="pmid">32338703</pub-id>
</mixed-citation></ref><ref id="ald240035r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name><surname>Liu</surname>
<given-names>ITT</given-names></string-name>, <string-name><surname>Kesselheim</surname>
<given-names>AS</given-names></string-name>, <string-name><surname>Cliff</surname>
<given-names>ERS</given-names></string-name></person-group>. <article-title>Clinical benefit and regulatory outcomes of cancer drugs receiving accelerated approval</article-title>. <source>JAMA</source>. <year>2024</year>;<volume>331</volume>(<issue>17</issue>):<fpage>1471</fpage>-<lpage>1479</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2024.2396</pub-id>
<pub-id pub-id-type="pmid">38583175</pub-id>
</mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ALD240035-1"><supplementary-material id="note-ALD240035-1-s" position="float" content-type="local-data"><label>Supplement.</label><caption><p>
Data Sharing Statement
</p></caption><media xlink:href="jamahealthforum-e244601-s001.pdf"/></supplementary-material></notes></back></article><!--requester-ID pruich-->